Literature DB >> 22693251

Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.

Xiaoli Du1, Xiaolan Qian, Alex Papageorge, Aaron J Schetter, William C Vass, Xi Liu, Richard Braverman, Ana I Robles, Douglas R Lowy.   

Abstract

Deleted in liver cancer 1 (DLC1), a tumor suppressor gene frequently inactivated in non-small cell lung cancer (NSCLC) and other malignancies, encodes a multidomain protein with a RhoGTPase-activating (RhoGAP) domain and a StAR-related lipid transfer (START) domain. However, no interacting macromolecule has been mapped to the DLC1 START domain. Caveolin-1 (CAV-1) functions as a tumor suppressor in most contexts and forms a complex with DLC1. Here, we have mapped the region of DLC1 required for interaction with CAV-1 to the DLC1 START domain. Mutation of the DLC1 START domain disrupted the interaction and colocalization with CAV-1. Moreover, DLC1 with a START domain mutation failed to suppress neoplastic growth, although it negatively regulated active Rho. CAV-1 and DLC1 expression levels were correlated in two public datasets of NSCLC lines and in two independent publicly available mRNA expression datasets of NSCLC tumors. Clinically, low DLC1 expression predicted a poor clinical outcome in patients with lung cancer. Together, our findings indicate that complex formation between the DLC1 START domain and CAV-1 contributes to DLC1 tumor suppression via a RhoGAP-independent mechanism, and suggest that DLC1 inactivation probably contributes to cancer progression. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22693251      PMCID: PMC6264793          DOI: 10.1158/0008-5472.CAN-12-0777

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  A PLCdelta1-binding protein, p122/RhoGAP, is localized in caveolin-enriched membrane domains and regulates caveolin internalization.

Authors:  Masaki Yamaga; Masayuki Sekimata; Makoto Fujii; Katsuhisa Kawai; Hideaki Kamata; Hajime Hirata; Yoshimi Homma; Hitoshi Yagisawa
Journal:  Genes Cells       Date:  2004-01       Impact factor: 1.891

Review 2.  Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.

Authors:  Fabien Alpy; Catherine Tomasetto
Journal:  J Cell Sci       Date:  2005-07-01       Impact factor: 5.285

3.  Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage.

Authors:  Kentaro Kato; Yasuhiro Hida; Masaki Miyamoto; Hideaki Hashida; Toshiya Shinohara; Tomoo Itoh; Shunichi Okushiba; Satoshi Kondo; Hiroyuki Katoh
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

4.  Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf.

Authors:  P H Anborgh; X Qian; A G Papageorge; W C Vass; J E DeClue; D R Lowy
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

5.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

6.  Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.

Authors:  Xiaolan Qian; Guorong Li; Holly K Asmussen; Laura Asnaghi; William C Vass; Richard Braverman; Kenneth M Yamada; Nicholas C Popescu; Alex G Papageorge; Douglas R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

7.  The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.

Authors:  Dandan Zhong; Jingfeng Zhang; Shuai Yang; Unice J K Soh; Jan Paul Buschdorf; Yi Ting Zhou; Daiwen Yang; Boon Chuan Low
Journal:  J Cell Sci       Date:  2009-02-01       Impact factor: 5.285

8.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

9.  Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer.

Authors:  Liqiang Xi; Andrew Feber; Vanita Gupta; Maoxin Wu; Andrew D Bergemann; Rodney J Landreneau; Virginia R Litle; Arjun Pennathur; James D Luketich; Tony E Godfrey
Journal:  Nucleic Acids Res       Date:  2008-10-16       Impact factor: 16.971

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  26 in total

1.  The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.

Authors:  Pratima Basak; Rachelle Dillon; Heather Leslie; Afshin Raouf; Michael R A Mowat
Journal:  BMC Cancer       Date:  2015-09-09       Impact factor: 4.430

2.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

3.  Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.

Authors:  David Sánchez-Martín; Atsushi Otsuka; Kenji Kabashima; Taekyu Ha; Dunrui Wang; Xiaolan Qian; Douglas R Lowy; Giovanna Tosato
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

4.  Fluctuation of ROS regulates proliferation and mediates inhibition of migration by reducing the interaction between DLC1 and CAV-1 in breast cancer cells.

Authors:  Bingwu Yang; Wenzhen Zhu; Zhaodi Zheng; Rongfei Chai; Shuhua Ji; Guanghui Ren; Tingting Liu; Zhaojun Liu; Taiyu Song; Fenglin Li; Shan Liu; Guorong Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-01-27       Impact factor: 2.416

5.  DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma.

Authors:  Cailing Yang; Dapeng Wu; Jinling Jia; Dong Liu; Zhanguo Li; Chunxiao Zhang; Min Li; Yonghua Xia
Journal:  Tumour Biol       Date:  2013-04-28

6.  Pathogenic mechanisms of lung adenocarcinoma in smokers and non-smokers determined by gene expression interrogation.

Authors:  Yunqian Hu; Guohan Chen
Journal:  Oncol Lett       Date:  2015-07-07       Impact factor: 2.967

7.  Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Authors:  Archna Ravi; Shelly Kaushik; Aarthi Ravichandran; Catherine Qiurong Pan; Boon Chuan Low
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

Review 8.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 9.  Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.

Authors:  Nicholas C Popescu; Steve Goodison
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

10.  In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.

Authors:  Drazen B Zimonjic; Lai N Chan; Veenu Tripathi; Jie Lu; Ohyun Kwon; Nicholas C Popescu; Douglas R Lowy; Fuyuhiko Tamanoi
Journal:  BMC Cancer       Date:  2013-04-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.